Increasing life expectancy in cystic fibrosis: Advances and challenges
- PMID: 34672432
- PMCID: PMC9004282
- DOI: 10.1002/ppul.25733
Increasing life expectancy in cystic fibrosis: Advances and challenges
Abstract
Since the first description of cystic fibrosis in 1938, there have been significant advances in both quality of life and longevity for people living with this disease. In this article we describe the milestones of the last 80 years and what we perceive to be the remaining barriers to normalcy for this population.
Keywords: CFTR modulators; cystic fibrosis; lung function; survival.
© 2021 Wiley Periodicals LLC.
Similar articles
-
Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.Br J Hosp Med (Lond). 2021 Nov 2;82(11):1-6. doi: 10.12968/hmed.2021.0530. Epub 2021 Nov 22. Br J Hosp Med (Lond). 2021. PMID: 34817261
-
Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.Drugs Today (Barc). 2013 Apr;49(4):253-60. doi: 10.1358/dot.2013.49.4.1940984. Drugs Today (Barc). 2013. PMID: 23616952
-
A new era for people with cystic fibrosis.Eur J Pediatr. 2021 Sep;180(9):2731-2739. doi: 10.1007/s00431-021-04168-y. Epub 2021 Jul 2. Eur J Pediatr. 2021. PMID: 34213646 Free PMC article. Review.
-
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.Cochrane Database Syst Rev. 2015 Mar 26;(3):CD009841. doi: 10.1002/14651858.CD009841.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2019 Jan 07;1:CD009841. doi: 10.1002/14651858.CD009841.pub3. PMID: 25811419 Updated. Review.
-
New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.Pediatr Clin North Am. 2016 Aug;63(4):751-64. doi: 10.1016/j.pcl.2016.04.006. Pediatr Clin North Am. 2016. PMID: 27469186 Free PMC article. Review.
Cited by
-
A Cross-Sectional Analysis of Paternal Intimacy Problems, Stress Levels, and Satisfaction from Families with Children Born with Mucoviscidosis.Int J Environ Res Public Health. 2022 Nov 16;19(22):15055. doi: 10.3390/ijerph192215055. Int J Environ Res Public Health. 2022. PMID: 36429771 Free PMC article.
-
Olfactory loss in people with cystic fibrosis: Community perceptions and impact.J Cyst Fibros. 2024 Nov;23(6):1195-1198. doi: 10.1016/j.jcf.2023.11.006. Epub 2023 Nov 18. J Cyst Fibros. 2024. PMID: 37981480
-
The current state of gastrointestinal motility evaluation in cystic fibrosis: a comprehensive literature review.Transl Gastroenterol Hepatol. 2023 Dec 6;9:10. doi: 10.21037/tgh-23-59. eCollection 2024. Transl Gastroenterol Hepatol. 2023. PMID: 38317748 Free PMC article. Review.
-
Factors associated with quality of life for cystic fibrosis family caregivers.Discov Ment Health. 2023 Oct 16;3(1):20. doi: 10.1007/s44192-023-00046-1. Discov Ment Health. 2023. PMID: 37982907 Free PMC article.
-
Cystic fibrosis hepatobiliary involvement: an update on imaging in diagnosis and monitoring.Pediatr Radiol. 2024 Aug;54(9):1416-1427. doi: 10.1007/s00247-024-05979-5. Epub 2024 Jul 22. Pediatr Radiol. 2024. PMID: 39039200 Review.
References
-
- Cystic Fibrosis Foundation Patient Registry. 2019 Annual Data Report. Bethesda, Maryland. ©2020 Cystic Fibrosis Foundation.
-
- Andersen DH. Cystic fibrosis of the pancreas and it’s relation to celiac disease. Am J Dis Child 1938;56(2):344.
-
- Di Sant’Agnese P, Darling R, Perera B, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics 1953;12(5):549–563. - PubMed
-
- Matthews LW, Doershuk CF, Wise M, Eddy G, Nudelman H, Spector S. A therapeutic regimen for patients with cystic fibrosis. J Pediatr 1964;65(4):558–575. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
